This inventor holds 1 USPTO granted patent. Top assignee: Seoul National University. Active years: 2023.
Company Filing History:
Years Active: 2023
Title: Min-Guk Han: Innovator in Cancer Treatment
Introduction
Min-Guk Han is a prominent inventor based in Gwangju, South Korea. He has made significant contributions to the field of cancer treatment, particularly focusing on innovative methods to combat metastatic triple negative breast cancer. His work is characterized by a blend of pharmaceutical advancements and therapeutic techniques.
Latest Patents
Min-Guk Han holds a patent for a groundbreaking method of treating metastatic triple negative breast cancer. The patent, titled "Method of treating metastatic triple negative breast cancer with radiotherapy combined with phosphatidyl inositol-3 kinase delta/gamma inhibitors and anti-PD-1 antibodies," outlines a pharmaceutical composition and treatment method that enhances the efficacy of radiotherapy. This innovative approach combines PD-1 blockade and PI3Kδγ inhibitors, demonstrating superior tumor inhibition and immune enhancement compared to traditional single-agent therapies. He has 1 patent to his name.
Career Highlights
Min-Guk Han is affiliated with Seoul National University, where he conducts research and develops new treatment methodologies. His academic background and research focus have positioned him as a key figure in the fight against aggressive forms of breast cancer. His dedication to improving patient outcomes through innovative therapies is commendable.
Collaborations
Min-Guk Han has collaborated with notable colleagues, including In-Ah Kim and Won-Ick Chang. These partnerships have fostered a collaborative environment that enhances research and development efforts in cancer treatment.
Conclusion
Min-Guk Han's contributions to cancer treatment through his innovative patent highlight his commitment to advancing medical science. His work not only represents a significant step forward in the treatment of triple negative breast cancer but also showcases the potential of combining various therapeutic agents for improved patient outcomes.